Enoxaparin looks simpler than a heparin drip — fixed dose, no aPTT, patients give it at home. That simplicity is exactly why its two real dangers get missed.
Low-molecular-weight heparins (LMWHs) — enoxaparin is the prototype — are short heparin fragments that bind antithrombin III but, because the chains are too short to bridge to thrombin, inactivate factor Xa almost exclusively with little activity against thrombin (factor IIa). That selectivity is why the aPTT barely moves and is NOT used to monitor LMWH. Absorption after subcutaneous injection is near-complete and predictable, so LMWH is given in fixed or weight-based doses without routine laboratory monitoring: enoxaparin 40 mg subcutaneously daily for prophylaxis, or 1 mg/kg every 12 hours for treatment. When a level is genuinely needed — significant renal impairment, pregnancy, obesity, or very low body weight — an anti-Xa level is drawn, not an aPTT. Because LMWH is cleared renally it accumulates when creatinine clearance falls below 30 mL/min, and the dose must be reduced. Administration technique is heavily tested and counterintuitive: the prefilled syringe contains an air bubble that must NOT be expelled, because it clears the last of the dose into the tissue; inject into the abdomen at least 2 inches from the umbilicus, at a 90-degree angle into a pinched skinfold, without aspirating and without massaging afterward, alternating sides with each dose. Enoxaparin carries an FDA boxed warning for spinal or epidural hematoma in clients receiving neuraxial anesthesia or undergoing spinal puncture — new back pain, leg numbness or weakness, or bowel or bladder dysfunction is an emergency, not a routine complaint. Protamine sulfate only partially reverses LMWH (roughly 60% of anti-Xa activity). HIT is less common than with UFH but still occurs, and a history of HIT contraindicates LMWH because the antibodies cross-react. LMWH does not cross the placenta, making it the anticoagulant of choice in pregnancy, where warfarin is teratogenic.
Key Distinctions
The single most-missed point: do NOT expel the air bubble from an enoxaparin prefilled syringe — the opposite of every other subcutaneous injection you have been taught. Match the drug to its lab: LMWH is not aPTT-monitored (that is UFH); if a level is needed it is an anti-Xa, and INR belongs to warfarin. Protamine fully reverses UFH but only partially reverses LMWH, so LMWH is the wrong choice when anticoagulation may need to be undone quickly or when renal function is poor. Lower HIT risk is not zero risk, and a prior HIT diagnosis rules LMWH out entirely. Finally, the boxed warning is about neuraxial procedures, not about bleeding in general — the assessment it demands is neurologic (back pain, leg weakness), not just a look at the injection site.
Clinical Pearl
Enoxaparin is heparin with the guesswork removed: fixed dose, no aPTT, and the patient can give it at home. Two things still bite — leave the air bubble IN the syringe, and treat new back pain or leg weakness after an epidural as a spinal hematoma until proven otherwise.